AUTHORS
Alessandro Criscimanna, MD, Jacques-Emmanuel Galimard2, Thomas Schroeder3, Tobias Gedde-Dahl4, Vesa Lindström5, Matthias Stelljes6, Peter Dreger, Prof. Dr. med.7, Igor Wolfgang Blau8, Inken Hilgendorf9, Stephan Mielke, MD10, Kristina Carlson, MD, PhD11, Roland Schroers12, Wolfgang Bethge, MD13, Yves Chalandon14, Eva Wagner Drouet15, Alexandros Spyridonidis16, Francesco Saraceni, MD17, Frederic Baron, MD18, Jaime Sanz, MD, PhD19, Mohamad Mohty, MD, PhD20, Fabio Ciceri21, Annalisa Ruggeri, MD22, Eolia Brissot, MD, PhD23
AFFILIATIONS
1 IRCCS San Raffaele Scientific Institute, Milan, Italy, Memorial Sloan Kettering Cancer Center, New York, United States
2 EBMT Paris Study Unit, Hôpital Saint-Antoine, Paris, France
3 University Hospital Essen, Essen, Germany
4 Oslo University Hospital, Rikshospitalet, Oslo, Norway
5 HUS Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
6 University Hospital Münster, Münster, Germany
7 Heidelberg University Hospital, Heidelberg, Germany
8 Charité – Universitätsmedizin Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany
9 Universiätsklinikum Jena, Klinik für Innere Medizin II, Jena, Germany
10 Karolinska University Hospital, Stockholm, Sweden
11 Uppsala University Hospital, Uppsala, Sweden
12 Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany
13 University Hospital Tübingen, Tübingen, Germany
14 Geneva University Hospitals (HUG), Hematology Service, and Faculty of Medicine, University of Geneva, Geneva, Switzerland
15 University Medical Center Mainz, Mainz, Germany
16 Bone Marrow Transplant Unit, University Hospital of Patras, Patras, Greece
17 Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
18 Department of Hematology, CHU of Liège, University of Liège, Liège, Belgium
19 Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
20 Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
21 IRCCS San Raffaele Scientific Institute, Milan, Italy
22 IRCCS San Raffaele Scientific Institute, Milan, Italy
23 Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
ABSTRACT
Background: Treosulfan/fludarabine (TreoFlu) is an established reduced-toxicity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT). Recently, prospective data have also demonstrated excellent safety and efficacy of myeloablative-dose TreoFlu (FT14 trial) in adults with AML in first complete remission (CR1). However, relapse remains the leading cause of treatment failure after HCT. The addition of melphalan (TreoFluMel) has been proposed to further enhance disease control while preserving the favorable toxicity profile. Comparative data are lacking.
Methods: We conducted a retrospective EBMT Acute Leukemia Working Party registry study including adults (≥18 years) with AML in CR1 undergoing first allo-HCT between 2010 and 2024. Cord blood and ex vivo T-cell-depleted graft recipients were excluded. Among 4,449 eligible patients (4,302 TreoFlu and 147 TreoFluMel), propensity score matching was performed to account for the imbalance in treatment group size and potential treatment allocation differences. Age at HCT, gender, year of transplantation, ELN2022 cytogenetic risk, donor type, CMV serostatus, and use of post-transplant cyclophosphamide (PTCy) were used as matching factors. The primary endpoint was 2-year overall survival (OS) with leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM), neutrophil and platelet engraftment, and acute/chronic graft-versus-host disease (GVHD) assessed as secondary outcomes.
Results: A total of 439 matched patients were analyzed, including 315 receiving TreoFlu and 124 receiving TreoFluMel. Median age at transplantation was 59.2 years (IQR, 50.9–65.2), and median follow-up was 2.3 years (95% CI, 2.0–2.7). ELN2022 cytogenetic risk was intermediate in 68.0% and 65.3% and adverse in 29.7% and 32.7% of TreoFlu and TreoFluMel recipients, respectively. KPS ≤80 was reported in 22.9% and 25.8% of patients, respectively (p = 0.52). GVHD prophylaxis consisted of PTCy-based regimens in 51.7% of patients, while 41.6% received ATG-based regimens. In the TreoFlu cohort, treosulfan was administered at 30, 36, and 42 g/m² in 48.3%, 13.8%, and 37.9% of patients, respectively. Within the TreoFluMel cohort, half of the patients received full-dose conditioning (Treo42/Mel140), whereas the remainder received reduced treosulfan only (n=12), reduced melphalan only (n=14), or dose reductions of both agents (n=42); dose information was incomplete for 13 patients. At 2 years, OS was 70.9% (95% CI, 64.7–76.2) after TreoFlu and 64.9% (95% CI, 54.8–73.2) after TreoFluMel (HR 1.41, 95% CI 0.94–2.10; P=0.10). LFS did not differ between groups (58.5%, 95% CI 52.0–64.4 vs 56.2%, 95% CI 45.9–65.2; HR 1.14, 95% CI 0.80–1.62; P=0.48). TreoFluMel was associated with delayed neutrophil recovery by day 30 (84.2% vs 92.0%) and platelet recovery by day 60 (80.9% vs 94.0%). The cumulative incidence of grade II–IV acute GVHD was similar between groups (HR 1.32, 95% CI 0.88–1.98; P=0.19), whereas grade III–IV acute GVHD occurred more frequently following TreoFluMel (13.1% vs 7.6%; HR 1.89, 95% CI 1.02–3.51; P=0.04). Two-year chronic GVHD incidence was non different (25.9%, 95% CI 17.4–35.2 vs 30.7%, 95% CI 24.7–36.8; HR 0.83, 95% CI 0.53–1.31; P=0.43). Relapse incidence did not differ between groups (22.4%, 95% CI 14.6–31.1 vs 31.7%, 95% CI 26.0–37.6; HR 0.71, 95% CI 0.46–1.12; P=0.14), but TreoFluMel recipients experienced a significantly higher non-relapse mortality (21.5%, 95% CI 14.5–29.5 vs 9.8%, 95% CI 6.6–13.8; HR 2.44, 95% CI 1.40–4.25; P=0.002). No significant interaction between conditioning regimen and age was observed for NRM. Relapse remained the leading cause of death (54.1%), whereas infection-related mortality accounted for a greater proportion of deaths after TreoFluMel than TreoFlu (42.1% vs 17.8%); GVHD-related mortality was similar between groups.
Conclusion: In this registry study, TreoFluMel was associated with increased NRM, delayed hematopoietic engraftment, higher rates of severe aGVHD, and more infection-related deaths, while showing no reduction in relapse incidence and no difference in leukemia-free or overall survival. Although residual confounding related to conditioning selection cannot be excluded because of the lack of MRD data and the non-randomized, center-driven treatment allocation, these findings suggest that any potential antileukemic benefit of adding melphalan may be outweighed by increased transplant-related toxicity.
DISCLOSURES
Alessandro Criscimanna, MD: No relevant conflicts of interest to declare.